COL4A3 is convincingly associated with autosomal recessive Alport syndrome, with an Definitive overall classification based on repeated identification of biallelic COL4A3 variants in affected individuals across multiple independent studies, segregation with disease in families, and concordant molecular data showing that COL4A3 defects disrupt type IV collagen biology PMID:7780062, PMID:11134255, PMID:24633401, PMID:22887978, PMID:33772369. The supplied evidence consistently supports autosomal recessive inheritance for COL4A3-related disease, while also showing that some heterozygous COL4A3 alleles can produce milder collagen IV nephropathy phenotypes outside the scope of this specific recessive assertion PMID:12028435, PMID:31477057.
Human genetic evidence for COL4A3 is substantial. A seminal case report described a girl with childhood hematuria and proteinuria, adolescent hearing loss, and kidney failure by age 20 years who carried a heterozygous 7-bp COL4A3 deletion from each carrier parent, establishing recessive segregation in a family with unaffected heterozygous parents PMID:7780062. Additional single-patient reports identified homozygous COL4A3 disease due to maternal isodisomy and due to homozygous missense variants in consanguineous or carrier-parent families, again with unaffected heterozygous parents PMID:27081500, PMID:31925849. Larger cohorts further replicated the association: COL4A3 mutations expected to be causative were identified during screening of 41 unrelated patients with autosomal Alport syndrome PMID:11134255; 30 genetically diagnosed patients from 24 pedigrees with autosomal recessive Alport syndrome included multiple individuals with biallelic COL4A3 variants PMID:24633401; 17 unrelated Chinese patients with autosomal recessive Alport syndrome had pathogenic variants in COL4A3 in 82% of probands PMID:22887978; and a retrospective series examined 49 patients from 41 families with autosomal recessive Alport syndrome, including COL4A3 cases, to define prognostic genotype groups PMID:35369551. A further registry-based study analyzed 101 patients with autosomal recessive Alport syndrome caused by COL4A3 or COL4A4 and confirmed genotype-phenotype correlations relevant to COL4A3 PMID:33772369.
The reported COL4A3 variant spectrum is broad and strongly consistent with disease causation. Biallelic COL4A3 variants include truncating, frameshift, splice-altering, in-frame deletion, start-loss, and glycine-substituting missense alleles, supporting allelic heterogeneity rather than reliance on a single recurrent change PMID:11134255, PMID:24633401, PMID:26809805. Illustrative COL4A3 variants reported in autosomal recessive Alport syndrome include c.4347_4353del (p.Arg1450fs), c.3266G>A (p.Gly1089Asp), c.1909G>A (p.Gly637Arg), c.4421T>C (p.Leu1474Pro), c.1891G>A (p.Gly631Arg), c.1409-5T>G, c.40_63del (p.Leu14_Leu21del), c.2371C>T (p.Arg791Ter), c.145-2A>G, c.1855G>A (p.Gly619Arg), c.3643C>T (p.Arg1215Ter), c.1A>C (p.Met1Leu), c.1315G>T (p.Gly439Cys), and c.4847G>A (p.Cys1616Tyr) PMID:7780062, PMID:27081500, PMID:31477057, PMID:31925849, PMID:17216251, PMID:22887978, PMID:24633401, PMID:33772369, PMID:37986374. Recurrent COL4A3 alleles such as c.40_63del (p.Leu14_Leu21del) were observed in multiple patients and were associated with milder heterozygous manifestations but severe disease in homozygous or compound heterozygous states, reinforcing recessive dosage effects for COL4A3 PMID:22887978.
The COL4A3 phenotype in autosomal recessive Alport syndrome is clinically characteristic and diagnostically useful. Across the supplied dataset, COL4A3-associated disease features include hematuria, proteinuria, progressive renal insufficiency, hearing impairment or sensorineural hearing loss, lenticonus, retinopathy, and progression to stage 5 chronic kidney disease or end-stage kidney disease PMID:7780062, PMID:31925849, PMID:30717457, PMID:33772369. A systematic review of 148 autosomal recessive Alport syndrome patients caused by COL4A3 or COL4A4 reported end-stage renal disease in about 62%, sensorineural hearing loss in 64%, ocular manifestations in 17%, median onset of hematuria at 2.5 years, hearing loss at 13 years, and end-stage renal disease at 21 years PMID:30717457. A genetically proven cohort of 30 patients from 24 pedigrees reported a median age of end-stage renal disease of 21 years, while a larger 49-patient series found median kidney failure onset at 27 years and showed worse prognosis when urinary-abnormality-causing variants were present on both alleles PMID:24633401, PMID:35369551. The 101-patient cohort also showed that patients with no missense variants had earlier hearing loss, nephrotic-range proteinuria, faster decline in kidney function, and earlier stage 5 chronic kidney disease than those with one or two missense variants, a pattern directly relevant to COL4A3 interpretation PMID:33772369.
Functional and experimental evidence supports pathogenicity of COL4A3 variants through disrupted collagen IV chain production, abnormal splicing, defective trimer biology, and podocyte stress responses. Early molecular work demonstrated splice-mediated insertion of an Alu-derived sequence into COL4A3 mRNA caused by c.4929-388G>T, with complete segregation in the family and direct proof that abnormal COL4A3 splicing can be pathogenic PMID:7633417. The original 1995 recessive case report predicted that the truncated COL4A3 chain would be unable to form trimers and would lack part of the NC1 domain PMID:7780062. In cellular and mouse studies, mutant COL4A3 caused intracellular retention, endoplasmic reticulum stress, unfolded protein response activation, and apoptosis, with a knock-in mouse showing a phenotype consistent with Alport syndrome and biopsy concordance in human COL4A3-associated disease PMID:24262798, PMID:31306228. These data provide biologic plausibility that damaging COL4A3 alleles impair basement membrane collagen assembly and injure podocytes.
Important caveats remain for clinical interpretation of individual COL4A3 variants. Several supplied studies emphasize that heterozygous COL4A3 variants can underlie benign familial hematuria or autosomal dominant Alport syndrome, so phase and zygosity are critical before assigning autosomal recessive Alport syndrome to COL4A3 PMID:12028435, PMID:17726307, PMID:31477057. Variant interpretation is also dynamic: a 2026 reassessment of Alport spectrum disorder cases found that 10 of 80 previously reported collagen IV variants were downgraded to uncertain significance and that 22 of 91 index cases had ambiguous results, underscoring the need for modern ACMG-style evaluation rather than accepting all legacy COL4A3 reports uncritically PMID:41851263. Some functional studies used overexpression systems or focused on selected variants, which support mechanism but do not validate every reported COL4A3 allele individually PMID:24262798, PMID:31306228. No conflicting evidence was provided in the supplied dataset that refutes the overall COL4A3–autosomal recessive Alport syndrome relationship.
Taken together, the supplied evidence shows that the COL4A3 gene is a well-established cause of autosomal recessive Alport syndrome, with repeated demonstration of biallelic COL4A3 variants in numerous unrelated patients and families, a disease-consistent phenotype, segregation with carrier parents, broad allelic heterogeneity, and supportive mechanistic data PMID:7780062, PMID:11134255, PMID:24633401, PMID:22887978, PMID:30717457, PMID:33772369. For diagnostic practice, detection of two pathogenic or likely pathogenic COL4A3 variants in trans in a patient with hematuria, proteinuria, progressive renal disease, and/or hearing or ocular findings is highly clinically actionable and strongly supports the diagnosis of autosomal recessive Alport syndrome. Key take-home: COL4A3 is a definitive autosomal recessive Alport syndrome gene, and biallelic pathogenic COL4A3 variants provide robust diagnostic evidence when interpreted with careful attention to phase, variant classification, and the known overlap between recessive and heterozygous collagen IV phenotypes.
Gene–Disease AssociationDefinitiveMultiple unrelated probands and cohorts with biallelic COL4A3 variants, consistent recessive segregation, characteristic Alport phenotype, and supportive functional data across independent studies. Genetic EvidenceDefinitiveRepeated reports of homozygous or compound heterozygous COL4A3 variants in affected individuals from numerous families and larger series, with recurrence and genotype-phenotype correlation. Functional EvidenceStrongAbnormal COL4A3 splicing, predicted loss of trimer formation, and cellular/mouse studies showing ER retention, unfolded protein response activation, and podocyte injury support pathogenic mechanism. |